# Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

> **NCT03884972** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Trabectedin
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03884972
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06-18
- **Primary completion:** 2020-03-04
- **Final completion:** 2020-03-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Request by sponsor due to no enrollment of participants on study
- **Last updated:** 2023-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03884972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03884972, "Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03884972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*